Healthcare Services

An Important Factor Driving the Pars Planitis Treatment Market Is the Increasing Prevalence Of Pars Planitis Fueling The Growth Of The Market Due To Advancements In Diagnosis And Rising Awareness

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Pars Planitis Treatment Market Evolve From 2026 To 2030?

The scale of the pars planitis treatment market has experienced robust expansion in recent times. This market is projected to expand from $683.54 billion in 2025 to $737.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. The expansion observed during the historical period can be ascribed to improved understanding of uveitis pathophysiology, availability of corticosteroid-based therapies, expansion of ophthalmology specialty clinics, increasing diagnostic imaging utilization, and growing clinical awareness of pars planitis.

The pars planitis treatment market size is anticipated to experience substantial expansion in the coming years. It is projected to reach $989.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period is attributable to factors such as the increasing adoption of personalized ophthalmic therapies, a rising demand for sustained inflammation control, the expansion of biologic drug development, a growing emphasis on strategies for vision preservation, and greater investment in advanced ophthalmic diagnostics. Key trends expected in the forecast period include the increasing application of immunomodulatory treatments, the rising utilization of biologic agents, a growing preference for targeted anti-inflammatory interventions, the advancement of sophisticated ocular surgical techniques, and an enhanced focus on early diagnosis and continuous disease monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Pars Planitis Treatment Market?

The anticipated increase in pars planitis cases is poised to drive the growth of the pars planitis treatment market. Pars planitis is an idiopathic form of intermediate uveitis, primarily causing inflammation in the vitreous and peripheral retina, typically affecting individuals aged 15 to 40. This rising prevalence is attributed to increased awareness and improved diagnostic capabilities, as advanced imaging tools allow for earlier and more accurate detection. Pars planitis treatments are crucial for managing the condition by reducing ocular inflammation, thus preserving vision and preventing complications. These therapies enhance patient care by providing targeted solutions like corticosteroids and immunosuppressants, which improve long-term eye health and quality of life. For instance, a case report from February 2025, published by Mega Journal of Case Reports, a US-based medical journal, stated that intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with pars planitis, its idiopathic form, representing 70% of these cases. Therefore, the increasing prevalence of pars planitis is a key factor boosting the pars planitis treatment market.

Which Segment Areas Are Covered In The Pars Planitis Treatment Market Analysis?

The pars planitis treatment market covered in this report is segmented –

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments

2) By Diagnosis: Blood Tests, Fundus Examination And Optical Coherence Tomography, Magnetic Resonance Imaging (MRI), Other Diagnosis

3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery

4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy

5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents

6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

What Trends Are Advancing Progress In The Pars Planitis Treatment Market?

Key players within the pars planitis treatment market are concentrating on developing advanced solutions, such as bispecific antibodies, with the aim of improving immune modulation, reducing ocular inflammation, and minimizing systemic side effects. Bispecific antibodies are engineered proteins designed to simultaneously bind to two distinct antigens or targets, thereby providing a more precise and effective treatment with fewer adverse effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) to treat retinal vein occlusion (RVO), in addition to its uses for age-related macular degeneration and diabetic macular edema. Vabysmo stands as the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), simultaneously addressing inflammation and vascular leakage. This innovative mechanism is currently being explored for application in intermediate uveitis, including pars planitis, where chronic inflammation in the retinal periphery necessitates durable and targeted intervention.

Which Global Companies Are Actively Competing In The Pars Planitis Treatment Market?

Major companies operating in the pars planitis treatment market are Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Quantum Cryogenics Ltd, Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Roche Holding AG, Pfizer Inc, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, UCB SA, Bausch Health Companies Inc

Read the full pars planitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

What Are The Leading Geographic Regions In The Pars Planitis Treatment Market?

North America was the largest region in the pars planitis treatment market in 2025. The regions covered in the pars planitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pars Planitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24649&type=smp

Browse Through More Reports Similar to the Global Pars Planitis Treatment Market 2026, By The Business Research Company

Hemoglobinopathies Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report

Hemoglobin Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report

Acquired Hemophilia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795